Q320 - The bright ray of sunshine companies had hoped for after dismal results in Q220

While Q220 is down in history as a disastrous quarter, marred by the dark mark of COVID-19, Q320 is the bright ray of sunshine companies in the US Joint Fluid Replacement market had hoped for.

For Q320, HA companies shared upbeat notes about renewed product demand, fueled by an uptick in activity from patients (out and about), distribution channels, and physicians treating an influx of new, as well as existing patients. One of the factors benefiting the HA market is the backlog of patients awaiting their turn for knee arthroplasty (TKA) and remain in need of treatment to manage their knee osteoarthritis (KOA) pain. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 US Joint Fluid Market Recap* are:

With restrictions lifted during Q320, the trauma segment rebounded from the prior quarter as procedural volumes increased and revenues hit pre-COVID levels.

In the absence of strict COVID restrictions, the jump ball went to the return of healthy trauma volumes during Q320. Major players cited quarterly growth in line with previous years. Q320 picked up the pace with the US Trauma Market leading the charge, up +4.6%, while the EU and ROW declined.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Trauma Market Recap* are:

The US Spinal Cord Stimulation Market saw a ray of sunshine in Q320 as revenues recovered to almost pre-COVID levels, but dark clouds lie ahead

Q320 was a ray of sunshine for the US Spinal Cord Stimulation (SCS) market as revenues returned to almost pre-COVID levels according to SmartTRAK Financial Dashboard. Sequentially, US revenues bounced sharply from Q220. Although OUS revenues weren’t as sunny, WW SCS revenues recovered in Q320, jumping ~60% sequentially from Q220 revenues.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Spinal Cord Stimulation Market Recap* are:

Orthopedic Robotic Installations Continued to Shatter Expectations in Q320

Orthopedic robotics is still in the early stages of adoption with SmartTRAK estimating that more than 25% of US hospitals have a robot and that fewer than 18% of TKA procedures in the US will have been performed robotically by YE2020. However, Stryker* noted in its Q320 earnings call that orthopedic robotic adoption (MAKO*) has started to reach an inflection point with an uptick in momentum that includes increasing interest, multiple installations in centers, placements into teaching hospitals and a shift to ASCs. Increasing competition from Zimmer Biomet’s* ROSA* and the launch of Smith & Nephew’s* CORI* second-generation robotic platform, has helped to push accounts that were thinking about purchasing a robot to follow through.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 CAS Ortho Market Recap* are:

Continuing robotic implant pull-through and achievement of enabling technology milestones reflect increasing importance of CAS Spine technology in Q320.

Similar to market dynamics in recon robotics, spine robotics are beginning to reach a tipping point in market acceptance. In its Q320 earnings call, CEO Dave Demski noted that Globus Medical* is seeing increasing interest in its Excelsius GPS* robot and that the Company is in a different part of the robotic adoption curve, with surgeons well beyond their initial skepticism as robots have become more mainstream. Globus and Medtronic* have the strongest positions in enabling technology and robotics in spine. However, competition will be heating up over the next several years.

SmartTRAK examines the Top 5 countries in Europe during the time of COVID-19 and estimates how the Advanced Wound Dressing Market will be impacted in 2020 and 2021.

Using an elbow bump instead of a handshake or hug is not the only new routine people have learned during the pandemic. As winter arrives with an expected surge in COVID-19, healthcare systems and services in Europe are building on lessons learned from the spring outbreak to help shape the way health services will be delivered in the coming months.

Amid this pandemic, several factors are affecting growth in the European Advanced Dressings Market, which is projected to reach ~$2.07B (€1.85B) by 2024 according to SmartTRAK estimates. In this article, SmartTRAK reviews how the COVID-19 pandemic has evolved in Europe and how it is impacting the market for Advanced Dressings in France, Germany, the UK, Spain and Italy.

Q3 makes a recovery from Q220 losses but gains remain below pre-COVID levels

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention-Vascular Access Adjunct Products market was down -1.8% YoY. Leading manufacturers in this segment hit hard in Q220 by COVID-19 restrictions and elective procedure cancellations reported positive growth over Q2, but are still not at pre-COVID-19 levels.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Infection Prevention: US Vascular Access Adjunct Market Recap* are:

Orthopedics market stages a third-quarter rally while navigating a new norm.

As the US healthcare system adjusts to the “new” norm brought on by the COVID-19 pandemic, the US Orthobiologics market rallied in Q320, ending the quarter up +2.3% YoY. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Orthobio Market Recap* are:

In Q320, Advanced Wound Care bounced back to almost normal levels amidst the COVID-19 pandemic with patients returning for chronic wound treatment.

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics increased slightly YoY.

3M* remained the WW market leader, up +1.5% YoY, driven by tentative signs of improvement in elective procedures. WW Advanced Dressings returned to positive growth, with mixed performance among leading players. US Skin/Dermal Substitute (CTP) revenue rebounded over Q319, driven by a whopping performance by Organogenesis, while WW NPWT was down slightly YoY, with single-use down and traditional devices flat.

Among the many topics covered in the comprehensive Q320 Advanced Wound Market Recap* are:

Return of elective procedures in Q320 fanned the flames of Extremities growth.

The return of elective procedures, along with the opening up of the US, fanned the flames of growth in the US with the Extremities Market returning to pre-COVID growth levels in Q320. Strength in both the Upper Extremities and Foot & Ankle Market fueled the fire with US Extremities heating up with +6.6% growth, according to SmartTRAK Financial Dashboard. The US Shoulder Replacement market segment brought the heat in US Upper Extremities which grew +6.3%, while Foot & Ankle Fixation and Ankle Replacement were also up, adding fuel to the fire in the Foot & Ankle market segment.